Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib 奥 希 替 尼
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III EGFR-標靶藥物是EGFR突變晚期非小細胞肺癌的第一線標準治療，主要是因為FLAURA臨床試驗的研究結果證實，相較於第一 Benjamin P. Levy, MD; Zofia Piotrowska, MD; Lyudmila A. Bazhenova, MD; and Jonathan W. Riess, MD, MS, consider the Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and 奥希替尼（英语：Osimertinib，又名奥沙替尼） 是一种用于治疗非小细胞肺癌的小分子靶向抗肿瘤药物， 它由阿斯利康公司开发，为第三代表皮生长因子受体抑制剂。该药物于2017年被 ...